New physiopathological and therapeutic approaches to diverticular disease of the colon

Bibliography

• PARKS TG: Natural history of diverticular disease of the colon. Clin. Gastroenterol. (1974) 4:53-69.
   Google Scholar
• BOLES JR RS, JORDAN SM: The clinical significance of diverticulosis. Gastroenterology (1958) 35(6):579-582.
   PubMed Web of Science ®Google Scholar
• AYDIN HN, REMZI FH: Diverticulitis: when and how to operate? Dig. Liver Dis. (2004) 36(7):435-445.
   PubMedGoogle Scholar
• FLOCH M, BINA I: The natural history of diverticulitis – fact and theory. J. Clin. Gastroenterol. (2004) 38(Suppl.1): S2-S7.
   Google Scholar
• ALDOORI WH, GIOVANNUCCI EL, RIMM EB et al.: A prospective study of diet and the risk of symptomatic diverticular disease in men. Am. J. Clin. Nutr. (1994) 60(5):757-64.
   PubMed Web of Science ®Google Scholar
• BERMAN LG, BURDICK D, HEITZMAN ER, PRIOR JT: A critical reappraisal of sigmoid peridiverticulitis. Surg. Gyn. Obstet. (1968) 127(3):481-491.
   PubMedGoogle Scholar
• KOHLER L, SAUERLAND S, NEUGEBAUER E: Diagnosis and treatment of diverticular disease: result of a Consensus development conference. The Scientific Committee of the European Association for Endoscopic Surgery. Surg. Endosc. (1999) 13(4):430-436.
   PubMed Web of Science ®Google Scholar
• TURSI A: Acute diverticulitis of the colon – Current medical therapeutic management. Expert Opin. Pharmacother. (2004) 5(1):145-149.
   Google Scholar
• SCHECHTER S, Mulvey J, Eisenstat TE: Management of uncomplicated acute diverticulitis: results of a survey. Dis. Colon Rectum (1999) 42(4):470-476.
   Google Scholar
• FERZOCO LB, Raptopoulos V, Silen W: Acute diverticulitis. N. Engl. J. Med. (1998) 338(21):1521-1526.
   PubMed Web of Science ®Google Scholar
• LAMANNA A, ORSI A: In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. Chemioterapia (1984) 3(6):365-367.
   PubMedGoogle Scholar
• PAPI C, CIACO A, KOCH M, CAPURSO L: Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol. Ther. (1995) 9(1):33-39.
   PubMedGoogle Scholar
• LATELLA G, PIMPO MT, SOTTILI S et al.: Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int. J. Colorectal Dis. (2003) 18(1):55-62.
   PubMed Web of Science ®Google Scholar
• TURSI A: Mesalazine for diverticular disease of the colon – a new role for an old drug. Expert Opin. Pharmacother. (2005) 6(1):69-74.
   PubMed Web of Science ®Google Scholar
• TURSI A, BRANDIMARTE G, GIORGETTI GM, ELISEI W: Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomised, open-label study. J. Clin. Gastroenterol. (2006) 40(4):312-316.
   Google Scholar
• TURSI A, BRANDIMARTE G, GIORGETTI GM, ELISEI W, AIELLO F: Balsalazide and/or high-potency probiotic mixture (VSL3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int. J. Colorectal Dis. (In press).
   Google Scholar
• FLOCH MH, FUCHS HM: Modification of stool content by increased bran intake. J. Clin. Nutr. (1978) 31(Suppl):185-189.
   Google Scholar
• ISOLAURI E, SÜTAS Y, KANKAAPÄÄ P, ARVILOMMI H, SALMINEN S: Probiotics: effect on immunity. Am. J. Clin. Nutr. (2001) 73(Suppl):444-450.
   PubMed Web of Science ®Google Scholar
• NARAYAN R, FLOCH MH: Microscopic colitis as part of the natural history of diverticular disease (Abstract). Am. J. Gastroenterol. (2002) 97(Suppl.): 112.
   Google Scholar
• MORINI S, HASSAN C, ZULLO A et al.: Epithelial cell proliferation of the colonic mucosa in diverticular disease: a case-control study. Aliment Pharmacol. Ther. (2005) 21(11):1385-1390.
   PubMedGoogle Scholar
• TURSI A, BRANDIMARTE G, ELISEI W, INCHINGOLO CD, AIELLO F: Epithelial cell proliferation of the colonic mucosa in different degrees of colonic diverticular disease. J. Clin. Gastroenterol. (2006) 40(4):306-311.
   Google Scholar
• RAMPTON DS: Diverticular colitis: diagnosis and management. Colorectal Dis. (2001) 3(3):149-513.
   PubMedGoogle Scholar
• KELLY JK: Polypoid prolapsing mucosal folds in diverticular disease. Am. J. Surg. Pathol. (1991) 15(9):871-878.
   PubMedGoogle Scholar
• SHEPERD NA: Colorectal submucosal mass lesions masquerading as chronic inflammatory bowel disease on mucosal biopsy. J. Pathol. (1995) 175(Suppl.): 119A
   Google Scholar
• LUDEMAN L, SHEPERD NA: What is diverticular colitis? Pathology (2002) 34(6):568-572.
   PubMed Web of Science ®Google Scholar
• TURSI A, BRANDIMARTE G, GIORGETTI GM, ELISEI W: Beclomethasone dipropionate plus VSL3 for the treatment of mild-to-moderate diverticular colitis: an open, pilot study. J. Clin. Gastroenterol. (2005) 39(7):644-646.
   Google Scholar
• HASSAN C, ZULLO A, IERARDI E, BURATTINI O, DE FRANCESCO V, MORINI S: Tumoral necrosis factor α downregulation and therapeutic response to infliximab in a case of segmental colitis associated with diverticula. Gut (2006) 55(4):589-590.
   PubMedGoogle Scholar
• SULTAN K, FIELDS S, PANAGOPOULOS G, KORELITZ BI: The nature of inflammatory bowel disease in patients with coexistent colonic diverticulosis. J. Clin. Gastroenterol. (2006) 40(4):317-321.
   Google Scholar
• WEST AB, LOSADA M: The pathology of diverticulosis coli. J. Clin. Gastroenterol. (2004) 38(Suppl. 1): S11-S16.
   Google Scholar
• GUSLANDI M: Segmental colitis: so what? Eur. J. Gastroenterol. Hepatol. (2003) 15(1):1-2.
   PubMedGoogle Scholar
• HANAUER SB: Medical therapy for ulcerative colitis 2004. Gastroenterology (2004) 126(6):1582-1592.
   PubMed Web of Science ®Google Scholar
• ELIAKIM R, RACHMILEWITZ D: Inflammatory mediators and the pathogenesis of inflammatory bowel disease. Ital. J. Gastroenterol. (1992) 24(6):361-368.
   PubMedGoogle Scholar
• GRISHAM MB: Oxidants and free radicals in inflammatory bowel disease. Lancet (1994) 344(8926):859-861.
   PubMed Web of Science ®Google Scholar
• HANAUER SB: Inflammatory bowel disease. N. Engl. J. Med. (1996) 334(13):841-848.
   PubMed Web of Science ®Google Scholar
• GONÇALVES E, ALMEIDA LM, DINIS TC: Antioxidant activity of 5-aminosalicylic acid against peroxidation of phosphatidylcholine liposomes in the presence of alpha-tocopherol: a synergistic interaction? Free Rad. Res. (1998) 29(1):53-66.
   PubMed Web of Science ®Google Scholar
• ROGLER G, ANDUS T: Cytokins in inflammatory bowel disease. World J. Surg. (1998) 22(4):382-389.
   PubMed Web of Science ®Google Scholar
• IZZO AA, MASCOLO N, CAPASSO F: Nitric oxide as a modulator of intestinal water and electrolyte transport. Dig. Dis. Sci. (1998) 43(8):1605-1620.
   PubMed Web of Science ®Google Scholar
• TRESPI E, COLLA C, PANIZZA P et al.: Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 year follow-up results. Minerva Gastroenterol. Dietol. (1999) 45(4):245-252.
   PubMedGoogle Scholar
• BRANDIMARTE G, TURSI A: Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Med. Sci. Monit. (2004) 10(5):170-173.
   Google Scholar
• DI MARIO F, ARAGONA G, LEANDRO G et al.: Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Dig. Dis. Sci. (2005) 50(3):581-586.
   PubMedGoogle Scholar
• TURSI A, BRANDIMARTE G, GIORGETTI GM, ELISEI W: Continuative versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. Dig. Dis. Sci. (In press).
   Google Scholar
• TURSI A, BRANDIMARTE G, DAFFINÀ R: Long-term treatment with mesalazine and rifaximin versus rifaximin alone for the patients with recurrent attacks of acute diverticulitis of the colon. Dig. Liver Dis. (2002) 34(7):510-515.
   PubMedGoogle Scholar
• BASSOTTI G, CHISTOLINI F, MORELLI A: Pathophysiological aspect of diverticular disease of colon and role of large bowel motility. World J. Gastroenterol. (2003) 9(10):2140-2142.
   PubMed Web of Science ®Google Scholar
• GUARNER F, SCHAAFSMA G: Probiotics. Int. J. Food Microbiol. (1998) 39(3):237-238.
   PubMed Web of Science ®Google Scholar
• SANDERS ME: Probiotics. Food Technol. (1999) 53:67-77.
   Google Scholar
• GIONCHETTI P, AMADINI C, RIZZELLO F et al.: Probiotics – role in inflammatory bowel disease. Dig. Liver Dis. (2002) 34 (Suppl.2):S58-S62.
   PubMedGoogle Scholar
• ISOLAURI E: Probiotics for infectious diarrhoea. Gut (2003) 52(3):436-437.
   PubMed Web of Science ®Google Scholar
• BAZZOCCHI G, GIONCHETTI P, ALMERIGI PF, AMADINI C, CAMPIERI M: Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Dig. Liver Dis. (2002) 34(Suppl.2): S48-S53.
   PubMedGoogle Scholar
• LUDEMAN L, WARREN BF, SHEPERD N: The pathology of diverticular disease. Best Pract. Res. Clin. Gastroenterol. (2002) 16(4):543-562.
   Google Scholar
• PEPPERCORN MA: The overlap of inflammatory bowel disease and diverticular disease. J. Clin. Gastroenterol. (2004) 38(5 Suppl): S8-S10.
   Google Scholar
• FRICČ P, ZAVORAL M: The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur. J. Gastroenterol.Hepatol. (2003) 15(3):313-315.
   PubMed Web of Science ®Google Scholar
• DRAGO L, DE VECCHI E, VALLI M, NICOLA L, LOMBARDI A, GISMONDO MR: Colonizzazione intestinale di Lactobacillus casei subsp. Casei I-1572 CNCM (L. casei DG) in volontari sani e in topi germ-free. Farmaci & Terapia (2002) XIX:72-76 (in Italian).
   Google Scholar
• VENTURI A, GIONCHETTI P, RIZZELLO F et al.: Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol. Ther. (1999) 13(8):1103-1108.
   PubMed Web of Science ®Google Scholar
• GIACCARI S, TRONCI S, FALCONIERI M, FERRIERI A: Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon. Eur. Rev. Med. Pharmacol. Sci. (1993) 15(1):29-34.
   Google Scholar
• TURSI A, BRANDIMARTE G, GIORGETTI GM: Assessment of small intestinal bacterial overgrowth in uncomplicated acute diverticulitis of the colon. World J. Gastroenterol. (2005) 11(18):2773-2776.
   PubMed Web of Science ®Google Scholar
• TURSI A, BRANDIMARTE G, GIORGETTI GM, NASI G: Assessment of orocecal transit time in different localisation of Crohn’s disease and its possibile influence on clinical response to therapy. Eur. J. Gastroenterol. Hepatol. (2003) 15(1):69-74.
   PubMedGoogle Scholar
• SCHREIBER S, HAMLING J, ZEHNTER E et al.: Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut (1997) 40(6):761-766.
   PubMed Web of Science ®Google Scholar
• KRUIS W, SCHREIBER S, THEUER D et al.: Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut (2001) 49(6):738-739.
   Google Scholar
• LEVINE DS, RIFF DS, PRUITT R et al.: A randomized, double blind, dose response comparison of balsalazide (6.75 g), balsalazide (2.25 g) and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am. J. Gastroenterol. (2002) 97(6):1398-1407.
   PubMed Web of Science ®Google Scholar
• PRUITT R, HANSON J, SAFDI M et al.: Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am. J. Gastroenterol. (2002) 97(12):3078-3086.
   PubMed Web of Science ®Google Scholar
• BORRUEL N, CASELLAS F, ANTOLIN M et al.: Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa. Am. J. Gastroenterol. (2003) 98(4):865-870.
   PubMed Web of Science ®Google Scholar
• STEFANSSON T, EKBOM A, SPAREN P, PÄHLMAN L: Association between sigmoid diverticulitis and left-sided colon cancer: a nested, population-based, case control study. Scand. J. Gastroenterol. (2004) 39(8):743-747.
   PubMed Web of Science ®Google Scholar
• MORINI S, HASSAN C, ZULLO A et al.: Diverticular disease as a risk factor for sigmoid adenomas. Dig. Liver Dis. (2002) 34(9):635-639.
   PubMedGoogle Scholar
• RONCUCCI L, SCALMATI A, PONZ DE LEON M: Pattern of cell kinetics in colorectal mucosa of patients with different types of adenomatous polyps of the large bowel. Cancer (1991) 68(4):873-878.
   PubMed Web of Science ®Google Scholar
• CHENG Y, DESREUMAUX P: 5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. World J. Gastroenterol. (2005) 11(3):309-314.
   Google Scholar